Clinical and Translational Results from a Phase II Trial of Imprime PGG, Alemtuzumab, and Rituximab in the Early Treatment of Patients with High Risk Chronic Lymphocytic Leukemia
- Resource Type
- Abstract
- Source
- In
Blood 6 December 2014 124(21):5662-5662 - Subject
- Language
- ISSN
- 0006-4971